HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fumitake Kai Selected Research

Fumitake Kai Research Topics

Disease

8Neoplasms (Cancer)
10/2020 - 01/2009
7Renal Cell Carcinoma (Grawitz Tumor)
07/2013 - 08/2005
4Breast Neoplasms (Breast Cancer)
10/2020 - 07/2009
1Non-Muscle Invasive Bladder Neoplasms
06/2015
1Wounds and Injuries (Trauma)
01/2014
1Hemorrhage
01/2014
1Pain (Aches)
01/2014
1Prostatic Neoplasms (Prostate Cancer)
11/2013
1Hypertension (High Blood Pressure)
07/2013
1Hypoxia (Hypoxemia)
01/2013
1Anemia
01/2013
1Cardiac Tamponade
01/2013
1Pericardial Effusion
01/2013
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2013
1Chronic Obstructive Pulmonary Disease (COPD)
01/2013
1Neoplasm Metastasis (Metastasis)
11/2011
1Margins of Excision
01/2009

Drug/Important Bio-Agent (IBA)

3CytokinesIBA
07/2013 - 08/2005
2Transcription Factors (Transcription Factor)IBA
04/2012 - 03/2010
2Cyclin D1IBA
04/2010 - 07/2009
2Thymidine PhosphorylaseIBA
01/2009 - 09/2006
2Proteins (Proteins, Gene)FDA Link
01/2009 - 09/2006
1EstersIBA
06/2015
1AcidsIBA
06/2015
1Docetaxel (Taxotere)FDA Link
11/2013
1Axitinib (AG 013736)IBA
07/2013
1temsirolimusFDA Link
01/2013
1C-Reactive ProteinIBA
11/2011
1Messenger RNA (mRNA)IBA
11/2010
1human ERBB2 proteinIBA
11/2010
1Biomarkers (Surrogate Marker)IBA
04/2010
1CyclinsIBA
04/2010
1Tumor Suppressor Protein p14ARF (p14ARF)IBA
04/2010
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2010
1DNA (Deoxyribonucleic Acid)IBA
04/2010
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
07/2009
1Cyclin EIBA
07/2009
1Progesterone Receptors (Progesterone Receptor)IBA
07/2009
1Pharmaceutical PreparationsIBA
05/2009
1Interferon-alpha (Interferon Alfa)IBA
05/2009
1InterferonsIBA
08/2005

Therapy/Procedure

3Therapeutics
10/2020 - 08/2005
2Castration
01/2014 - 11/2013
2Nephrectomy
06/2011 - 01/2009
1Oral Administration
06/2015
1Spinal Anesthesia
01/2014
1Salvage Therapy
11/2013
1Adrenalectomy
01/2013
1Aftercare (After-Treatment)
01/2013